Association between testosterone replacement therapy and cardiovascular events in men: a retrospective propensity-weighted analysis
The Journal of Sexual Medicine · 2026
DOI: 10.1093/jsxmed/qdaf306 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Sexual Medicine, 2026. Verfasst von Dhiraj S Bal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, R3E 0T4, Canada. Hauptthemen laut MEDLINE: Testosterone, Hormone Replacement Therapy, Cardiovascular Diseases, Hypogonadism. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Surgery GFT Research Grant.
Abstract (Originalsprache)
Background
Testosterone deficiency (TD), or male hypogonadism, affects up to 25% of Canadian men aged 40 to 60. Testosterone replacement therapy (TRT) is widely used to manage symptoms of TD. Despite over seven decades of clinical use, the relationship between TRT and major adverse cardiovascular events (MACE) remains unclear.
Aim
To investigate the association between TRT and MACE using a large population-based database.
Methods
A propensity-weighted, retrospective cohort study was conducted using provincial health administrative databases. Men were eligible if they had no prior TRT use or MACE and maintained at least one year of provincial health coverage between April 1, 1995, and December 31, 2018. TRT was defined as having at least two prescriptions filled within one year for testosterone products (capsules, gels, patches, or injections). MACE was defined as the first occurrence of myocardial infarction, coronary revascularization, ischemic stroke, or hospitalization for heart failure. A logistic regression model including age, socioeconomic status, index year, diabetes, hypertension, dyslipidemia, and renal disease generated propensity scores. Stabilized inverse propensity treatment weighting was applied. Outcomes A Cox proportional hazards model was used to assess time to first MACE.
Results
Among 6949 men who received TRT and 415 837 controls, TRT was associated with a 27% increased risk of MACE (HR 1.27, 95% CI: 1.16-1.39) in weighted analyses. Among 7306 men diagnosed with TD and 442 602 matched controls, those with TD also showed a 27% increased risk of MACE (HR 1.27, 95% CI: 1.16-1.39). Median time to MACE was 2828 days in the TRT group and 2707 days in controls. MACE occurred in 9.95% of TRT users versus 5.56% of controls. Clinical Implications Clinicians should be aware that both TRT and underlying TD are associated with increased cardiovascular risk. Assessment of comorbidities and patient-specific cardiovascular risk remains essential when initiating TRT. Strengths & Limitations This study leverages a large, real-world, population-based dataset with robust propensity weighting methodology. However, unmeasured confounding such as obesity, smoking, or physical activity levels may influence outcomes. Diagnostic coding limitations may also affect TD case identification.
Conclusions
Both TRT use and TD were associated with a significantly increased risk of MACE. Whether TRT independently drives this risk or merely reflects underlying disease requires further investigation. Risk stratification and shared decision-making should guide the initiation of TRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, R3E 0T4, Canada.
- Department of Surgery, University of Manitoba, Winnipeg, MB, R3A 1R9, Canada.
- Chronic Disease Innovation Center, Winnipeg, MB, R2V 4W1, Canada.
ORCID-Profile: Dhiraj S Bal
Förderung
- Department of Surgery GFT Research Grant
Zitieren
APA
Bal, D. S., Fidel, M. G., Panchendrabose, K., Mann, U., Brar, R., & Patel, P. (2026). Association between testosterone replacement therapy and cardiovascular events in men: a retrospective propensity-weighted analysis. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdaf306
Vancouver
Bal DS, Fidel MG, Panchendrabose K, Mann U, Brar R, Patel P. Association between testosterone replacement therapy and cardiovascular events in men: a retrospective propensity-weighted analysis. The Journal of Sexual Medicine. 2026. doi:10.1093/jsxmed/qdaf306
BibTeX
@article{Bal2026,
author = {Bal, Dhiraj S and Fidel, Maximilian G and Panchendrabose, Kapilan and Mann, Uday and Brar, Ranveer and Patel, Premal},
title = {Association between testosterone replacement therapy and cardiovascular events in men: a retrospective propensity-weighted analysis},
journal = {The Journal of Sexual Medicine},
year = {2026},
doi = {10.1093/jsxmed/qdaf306}
}
EUVIMED